Mandate

Vinge advises Sigrid Therapeuctis AB on share issues

November 27, 2017

Vinge has advised Sigrid Therapeuctis AB in connection with a combined directed issue and rights offering.

Sigrid Therapeutics is pioneering a user-friendly product made of precisely engineered particles with extraordinary absorptive capacity. The product works mechanically in the gut to improve glycemic control in a safe and effective way.

Vinge’s team primarily consisted of Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026